Status:
UNKNOWN
Multi Dimensional Precise Exploration of Immunoconsolidation Therapy for Locally Advanced NSCLC After Chemo-radiotherapy
Lead Sponsor:
Fudan University
Conditions:
NSCLC
Chemoradiotherapy
Eligibility:
All Genders
18-80 years
Brief Summary
The purpose of this study is to carry out a prospective observational study in patients with locally advanced NSCLC receiving radical concurrent chemoradiotherapy and follow-up immune consolidation th...
Eligibility Criteria
Inclusion
- Non small cell lung cancer patients confirmed by pathology;
- They were 18-80 years old;
- The tumor could not be resected or could not tolerate surgery;
- Planed to receive chemoradiotherapy and subsequent immunoconsolidation therapy;
- Clinical stage III (AJCC, 8th Edition, 2017);
- After systematic detection of non-small cell lung cancer core indicators including EGFR, ALK, ros1, KRAS, ntrk, TMB, etc;
- Patient informed consent.
Exclusion
- After radiotherapy and chemotherapy, the disease progressed and immune maintenance therapy could not be carried out
- It can not cooperate with the completion of baseline mutation screening and subsequent sample detection
- Factors judged by other researchers not suitable for further study
Key Trial Info
Start Date :
April 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04741633
Start Date
April 1 2020
End Date
December 31 2022
Last Update
February 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032